FDA Manufacturing Inspections To Focus On Sterile, New Facilities In FY 2003
This article was originally published in The Tan Sheet
Executive Summary
FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11
You may also be interested in...
FDA GMP Initiative Shifts Warning Letter Review Back To Centers
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of FDA's initiative to create a risk-based approach to pharmaceutical manufacturing
OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC